OTC · Biotechnology

Cynata Therapeutics Limited (CYYNF) Stock

$0.00 OTC: CYYNF Healthcare

Cynata Therapeutics Limited, an Australian biotechnology company headquartered in Cremorne, specializes in developing and bringing to market its unique Cymerus™ mesenchymal stem cell (MSC) technology for a wide array of human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully completed Phase I clinical trials addressing graft-versus-host disease (GvHD).

Valuation

MetricValue
Price$0.00
Market Cap$973817
P/E Ratio-0.33
P/B Ratio0.41
P/S Ratio0.58
EPS (TTM)$-0.03
52-Week High$0.22
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-112.99%
ROA-62.05%
ROCE-425.79%
Gross Margin100.00%
Operating Margin-150.23%
Net Margin-450.00%
Debt/Equity0.00
Current Ratio2.49

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.0M$8.0M$2.0M$2.0M$2.0M
Operating Profit$-6.0M$-4.0M$-13.0M$-9.0M$-8.0M
Net Profit$-8.0M$-5.0M$-14.0M$-10.0M$-9.0M
EPS$-0.06$-0.04$-0.10$-0.05$-0.05
Op Margin-375.6%-55.2%-785.8%-380.4%-430.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$30.0M$27.0M$19.0M$8.0M$7.0M
Total Liabilities$2.0M$3.0M$2.0M$1.0M$1.0M
Cash$27.0M$24.0M$16.0M$6.0M$5.0M
Borrowings$0$0$0$0$0

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-5.0M$-3.0M$-14.0M$-10.0M$-9.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$-1.0M
Net Cash Flow$13.0M$-3.0M$-8.0M$-10.0M$-1.0M
Free Cash Flow$-5.0M$-3.0M$-14.0M$-10.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-0.03
FCF Yield-278.29%
Quick Ratio2.49
Interest Coverage0.00
Return 1Y-95.00%
Return 3Y-95.56%
Return 5Y—

Ownership

Insiders Held24.97%
Institutions Held8.23%
Institutions Float Held10.97%
Institutional HolderSharesReport Date
DFA Asia Pacific Small Company Series10,7922023-04-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CBSTFCubeSmart $0.03 +0.00% -0.11 $14.48M 0.00%
DSOLDrug Free Solution, Inc. $0.00 — -16.94 $113361 0.00%
DTCFFDefence Therapeutics Inc. $0.29 +9.96% -3.58 $22.25M 0.00%
MDDVFMedical Developments International Limited $0.37 +0.00% -123.08 $41.68M 0.00%
MMIRFMedMira Inc. $0.04 +0.00% -15.91 $28.07M 0.00%

About Cynata Therapeutics Limited

Cynata Therapeutics Limited, an Australian biotechnology company headquartered in Cremorne, specializes in developing and bringing to market its unique Cymerus™ mesenchymal stem cell (MSC) technology for a wide array of human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully completed Phase I clinical trials addressing graft-versus-host disease (GvHD). Beyond this, its development pipeline features CYP-004, currently in Phase III clinical trials for osteoarthritis, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. The company is also actively investigating treatments for numerous other medical conditions, including asthma, myocardial infarction (heart attack), coronary artery disease, acute respiratory distress syndrome (ARDS), brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis (IPF), and opportunities in renal transplantation. Crucially, Cynata has forged a strategic partnership with Fujifilm, which provides essential clinical and commercial manufacturing and supply services for its Cymerus-based therapeutic MSC products. Originally incorporated in 2003 as Eco Quest Limited, the company rebranded as Cynata Therapeutics Limited in October 2013.

Cynata Therapeutics Limited (CYYNF) stock trades at $0.00 with a market capitalization of $973817. The stock is valued at a price-to-earnings (P/E) ratio of -0.33, price-to-book of 0.41, price-to-sales of 0.58. Over the past 52 weeks the stock has ranged between $0.00 and $0.22, and currently trades 100.0% below its 52-week high.

On profitability, Cynata Therapeutics Limited generates a return on equity (ROE) of -112.99%, return on capital employed of -425.79%, an operating margin of -150.23%, a net profit margin of -450.00%.

Official website: www.cynata.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides